DOP2016000003A - Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán - Google Patents

Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán

Info

Publication number
DOP2016000003A
DOP2016000003A DO2016000003A DO2016000003A DOP2016000003A DO P2016000003 A DOP2016000003 A DO P2016000003A DO 2016000003 A DO2016000003 A DO 2016000003A DO 2016000003 A DO2016000003 A DO 2016000003A DO P2016000003 A DOP2016000003 A DO P2016000003A
Authority
DO
Dominican Republic
Prior art keywords
pharmaceutical dosage
dosage forms
include back
methods
stabilized pharmaceutical
Prior art date
Application number
DO2016000003A
Other languages
English (en)
Inventor
Ye Huang
Katherine E Peterson
Andrew K Koski
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of DOP2016000003A publication Critical patent/DOP2016000003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Abstract

(A) FORMAS DE DOSIFICACIÓN FARMACÉUTICAS ESTABILIZADAS QUE COMPRENDEN ATRASENTÁN, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO Y, OPCIONALMENTE, OTRO AGENTE TERAPÉUTICO; (B) MÉTODOS DE USO DE DICHAS FORMAS DE DOSIFICACIÓN FARMACÉUTICAS PARA TRATAR UNA NEFROPATÍA, ENFERMEDAD RENAL CRÓNICA Y/U OTRAS CONDICIONES; (C) CONJUNTOS DE ELEMENTOS [KITS]QUE COMPRENDEN DICHAS FORMAS DE DOSIFICACIÓN FARMACÉUTICAS Y, OPCIONALMENTE, UNA SEGUNDA FORMA DE DOSIFICACIÓN FARMACÉUTICA QUE COMPRENDE OTRO AGENTE TERAPÉUTICO; (D) MÉTODOS PARA LA PREPARACIÓN DE DICHAS FORMAS DE DOSIFICACIÓN FARMACÉUTICAS; Y (E) FORMAS DE DOSIFICACIÓN FARMACÉUTICAS PREPARADAS MEDIANTE DICHOS MÉTODOS.
DO2016000003A 2013-07-08 2016-01-06 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán DOP2016000003A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361843799P 2013-07-08 2013-07-08

Publications (1)

Publication Number Publication Date
DOP2016000003A true DOP2016000003A (es) 2016-02-15

Family

ID=51211921

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2016000003A DOP2016000003A (es) 2013-07-08 2016-01-06 Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán

Country Status (19)

Country Link
US (2) US9364458B2 (es)
EP (1) EP3019158A1 (es)
JP (1) JP2016530238A (es)
KR (1) KR20160029125A (es)
CN (1) CN105517541A (es)
AU (1) AU2014287496A1 (es)
CA (1) CA2916033C (es)
CL (2) CL2016000027A1 (es)
CR (1) CR20160037A (es)
DO (1) DOP2016000003A (es)
EC (1) ECSP16005195A (es)
HK (1) HK1223825A1 (es)
IL (1) IL243242B (es)
MX (1) MX2016000188A (es)
PE (1) PE20160221A1 (es)
PH (1) PH12016500042A1 (es)
RU (1) RU2016103764A (es)
SG (2) SG10201700596PA (es)
WO (1) WO2015006219A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014287496A1 (en) * 2013-07-08 2016-01-07 Abbvie, Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
US10929741B2 (en) 2018-06-18 2021-02-23 University Of Florida Research Foundation, Incorporated Cross-registration for unclonable chipless RFID tags
CA3161516A1 (en) * 2019-12-17 2021-06-24 Philip Thomas FROHLICH Methods of treating iga nephropathy with atrasentan
EP4178578A1 (en) 2020-07-10 2023-05-17 Astrazeneca AB Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
WO2024092240A1 (en) 2022-10-28 2024-05-02 Chinook Therapeutics, Inc. Treatment of iga nephropathy using an endothelin receptor antagonist and an april binding antibody

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US7208517B1 (en) 1994-08-19 2007-04-24 Abbott Labortories Endothelin antagonists
US7365093B2 (en) 1994-08-19 2008-04-29 Abbott Laboratories Endothelin antagonists
US5767144A (en) 1994-08-19 1998-06-16 Abbott Laboratories Endothelin antagonists
US6946481B1 (en) 1994-08-19 2005-09-20 Abbott Laboratories Endothelin antagonists
US6162927A (en) 1994-08-19 2000-12-19 Abbott Laboratories Endothelin antagonists
US6124341A (en) 1996-02-13 2000-09-26 Abbott Laboratories Endothelin antagonists
US5801250A (en) 1996-12-13 1998-09-01 Abbott Laboratories Process for the stereoselective production of nitro-enamine compounds
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
JP2002524546A (ja) 1998-09-14 2002-08-06 アボット・ラボラトリーズ 立体選択性ニトロ化合物の製造方法
US20020055457A1 (en) 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
US20030092757A1 (en) 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US20030022811A1 (en) 2001-04-11 2003-01-30 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
WO2006034234A1 (en) 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 3 of atrasentan hydrochloride
US20060135596A1 (en) 2004-09-17 2006-06-22 Zhang Geoff G Amorphous form of a drug
MX2007003158A (es) 2004-09-17 2007-05-15 Abbott Lab Forma cristalina 2 del clorhidrato de atrasentan.
WO2006034094A1 (en) * 2004-09-17 2006-03-30 Abbott Laboratories Crystalline form 1 of atrasentan hxdrochloride
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
US20080132710A1 (en) 2006-12-04 2008-06-05 Abbott Laboratories Atrasentan hydrochloride crystalline form 2
US20100184026A1 (en) 2009-01-22 2010-07-22 Abbott Laboratories Companion Diagnostic Assays For Endothelin Receptor Antagonists
EP2515883A4 (en) * 2009-12-22 2013-07-17 Abbvie Inc CAPSULE OF ABT-263
KR20110119108A (ko) 2010-04-26 2011-11-02 울산대학교 산학협력단 포도씨 프로안토시아니딘 추출물을 유효성분으로 함유하는 폐 섬유화증 치료 및 예방용 약학조성물
CN102114005B (zh) * 2010-12-06 2012-12-12 武汉武药科技有限公司 一种波生坦胶囊及其制备方法
AU2014287496A1 (en) * 2013-07-08 2016-01-07 Abbvie, Inc. Stabilized pharmaceutical dosage forms comprising atrasentan
US8962675B1 (en) * 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts

Also Published As

Publication number Publication date
AU2014287496A1 (en) 2016-01-07
SG10201700596PA (en) 2017-02-27
EP3019158A1 (en) 2016-05-18
SG11201600107RA (en) 2016-02-26
CL2016000788A1 (es) 2016-11-11
IL243242A0 (en) 2016-02-29
PE20160221A1 (es) 2016-05-22
US10016393B2 (en) 2018-07-10
CL2016000027A1 (es) 2016-07-22
US20160250186A1 (en) 2016-09-01
RU2016103764A3 (es) 2018-05-31
KR20160029125A (ko) 2016-03-14
CA2916033C (en) 2022-08-23
JP2016530238A (ja) 2016-09-29
CN105517541A (zh) 2016-04-20
US20150011602A1 (en) 2015-01-08
CR20160037A (es) 2016-04-05
WO2015006219A1 (en) 2015-01-15
IL243242B (en) 2020-11-30
US9364458B2 (en) 2016-06-14
ECSP16005195A (es) 2017-02-24
CA2916033A1 (en) 2015-01-15
MX2016000188A (es) 2016-03-09
HK1223825A1 (zh) 2017-08-11
RU2016103764A (ru) 2017-08-11
PH12016500042A1 (en) 2016-03-28

Similar Documents

Publication Publication Date Title
CL2015003022A1 (es) Uso de empagliflozina en la preparacion de un medicamento util en el tratamiento de la enfermedad renal cronica
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CO7310528A2 (es) Composición farmacéutica recubierta que contiene regorafenib
DOP2016000003A (es) Formas de dosificación farmacéuticas estabilizadas que comprenden atrasentán
BR112016012506A8 (pt) combinações farmacêuticas, seus usos, e uso de um portador de dados
BR112015025464A2 (pt) coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico
CL2015003072A1 (es) Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
CL2015002733A1 (es) Composición farmacéutica de clorhidrato de s-cetamina.
CL2013002033A1 (es) Preparacion oral de desintegracion rapida que comprende granulos que comprenden un medicamento, un agente de desintegracion, un aglutinador, un agente de enmascaramiento y un agente de solubilizacion; metodo de preparacion; su uso para la profilaxis y/o tratamiento de un padecimiento bipolar.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2017000050A1 (es) Terapia de combinación para el cáncer
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112015028890A2 (pt) derivados de piridona para o tratamento de infecções virais e outras doenças
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
CL2014003072A1 (es) Uso de un compuesto 2-((2r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida (veliparib o abt-888) o de una sal farmaceuticamente aceptable que sirve para el tratamiento de las metástasis en el cerebro con una combinación de una terapia con radiación en la totalidad del cerebro.
ES2639588R1 (es) Uso de una sal de tungsteno (VI) para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético